


PHARMACEUTICAL 2018

Loxo Oncology Inc. Rank 101 of 349





PHARMACEUTICAL 2018

Loxo Oncology Inc. Rank 101 of 349

The relative strengths and weaknesses of Loxo Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Loxo Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 169% points. The greatest weakness of Loxo Oncology Inc. is the variable Revenues, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is -32%, being 246% points above the market average of -278%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 781,807 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 221,570 |
| Liabilities, Non-Current | 0 |
| Other Assets | 723 |
| Other Compr. Net Income | -551 |
| Other Expenses | 0 |
| Other Liabilities | 183,662 |
| Other Net Income | 24,820 |
| Property and Equipment | 912 |
| Research and Development | 140,039 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 33,657 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 783,442 |
| Liabilities | 405,232 |
| Expenses | 173,696 |
| Stockholders Equity | 378,210 |
| Net Income | -148,876 |
| Comprehensive Net Income | -149,152 |
| Economic Capital Ratio | -32% |